The following stories appear in full on today's Vidyya Medical News Service Web site.
Merck announced today that the Food and Drug Administration has granted an additional six months of U.S. marketing exclusivity to Pepcid® (famotidine) in response to a supplemental new drug application (sNDA) the Company filed on pediatric studies.
The use of Pepcid® in children is supported by evidence from published studies in small numbers of children and by adequate and well-controlled studies in adults. Treatment duration and dosage in children should be individualized based on clinical response and/or gastric pH determination and endoscopy. Get the prescribing information in today's issue.
How much is too much antibiotic when treating Lyme disease? Give too much and even though your patients get better and are happy with their treatment, you may still lose your license. Some truths are stranger than fiction, and in this age of managed care and insurance review boards the odd is becoming commonplace. We have a brief story of a physician facing discipline for treating his patients too well.
Most individuals with Lyme disease respond well to antibiotics and have full recovery. In a few patients symptoms of persisting infection may continue or recur, requiring additional antibiotic treatment. Varying degrees of permanent joint or nervous system damage may develop in patients with late chronic Lyme disease. In rare cases, death may occur. Save this patient education handout for your patients.
The Food and Drug Administration is again warning consumers of products marketed as dietary supplements that contain tiratricol, also known as triiodothyroacetic acid or TRIAC, a potent thyroid hormone that may cause serious health consequences including heart attacks and strokes. Despite four recalls over the past seven months, various products that contain tiratricol may still have reached consumers. FDA urges all consumers to stop using such products immediately.
As always, we hope you enjoy the issue.